🔎 Trials Near Me

Gara Jalqabaatti › Kansaar Onnee Triple-Negative › Massachusetts

Qorannoo klinikaalii Kansaar Onnee Triple-Negative Massachusetts keessatti

Qorannoo 26 Kansaar Onnee Triple-Negative f Massachusetts keessatti hirmaatuu jiru.

Magaalota Massachusetts keessatti

Takkalaa qorannoo (Ingiliffa)

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • Massachusetts General Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06465069

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT04585750

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

  • Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 19 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06586957

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

  • Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT05422794

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  • Massachusetts General Hospital Cancer Center ( Site 0091), Boston
  • Dana Farber Cancer Institute ( Site 0090), Boston
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06966700

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT05983432

A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer

  • Massachusetts General Hospital, Boston
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT07513311

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT06657222

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  • Massachusetts General Hospital, Boston
  • Beth Israel Deaconess Medical Center, Boston
  • Dana Farber Cancer Institute, Boston
  • fi 4 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Ful-2026 · NCT05633654

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

  • Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Hag-2026 · NCT07029399

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, Boston
  • Normunity Investigational Site, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Hag-2026 · NCT07182149

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

  • Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Hag-2026 · NCT07341867

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Hag-2026 · NCT06926868

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

  • Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 06-Hag-2026 · NCT06176261

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Hag-2026 · NCT05579366

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

  • Massachusetts General Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 100 · Saalaa hunda · Haaromfame 29-Ado-2026 · NCT06562192

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ado-2026 · NCT06150664

Sacituzumab Govitecan In TNBC

  • Dana Farber Cancer Institute, Boston
  • Massachusetts General Hospital, Boston
  • Massachusetts General Hospital - North Shore Cancer Center, Danvers
  • fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Ado-2026 · NCT04230109

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

  • Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Ado-2026 · NCT07137416

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Wax-2026 · NCT05377996

A Study of LY4175408 in Participants With Advanced Cancer

  • Massachusetts General Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Wax-2026 · NCT07046923

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

  • Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Cam-2026 · NCT04434040

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

  • Dana Farber Cancer Institute, Boston
  • DFCI @ Foxborough, Foxborough
  • DFCI @ Milford Regional Hospital, Milford
  • fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Elb-2026 · NCT04468061

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

  • Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Elb-2026 · NCT06451497

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

  • Massachusetts General Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Bit-2026 · NCT06908928

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

  • Massachusetts General Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Sad-2024 · NCT04787042

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.